# The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection

> **NCT00556504** · PHASE2 · COMPLETED · sponsor: **TCM Biotech International Corp.** · enrollment: 84 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** TCM-700C
- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Ribavirin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00556504
- **Lead sponsor:** TCM Biotech International Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2011-01
- **Final completion:** 2011-05
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2014-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00556504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00556504, "The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT00556504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*